Lumida
/CLB
⌘K
Core Laboratories Inc

Core Laboratories Inc

CLB
$12.50USD-0.24%-0.03 today

MARKET CAP

573.6M

P/E (TTM)

20.5x

FWD P/E

DAY RANGE

$12 – $13

52W RANGE

$10
$20

AI Summary

Stalk
Buy NowMedium

CLB is in a Stage 4 decline but is mean-reversion eligible, warranting a tactical bullish stance. The post-capitulation pattern and extreme oversold context signal supply exhaustion and potential stabilization around the washout low, and short-term price action shows a strong recovery bar with volume confirming initial acceptance, supporting immediate participation on this rebound.

  • Q4 2025 revenue reached $138.3M, up 3% QoQ and 7% YoY.
  • Repurchased $2.7M in stock in Q2 2026, seventh consecutive buyback.
  • Q2 2026 net income fell to $5.1M, down 72% QoQ.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$509.8M$523.8M$526.5M
YoY %+2.8%+0.5%
P / Sales1.6x1.6x1.4x
EV / Sales2.3x2.2x2.0x
Gross Profit, Adj.$109.8M$103.3M$108.9M
YoY %-5.9%+5.4%
Margin %21.5%19.7%20.7%
EV / Gross Profit10.7x11.0x9.6x
EBITDA, Adj.$70.4M$73.5M$71.1M
YoY %+4.4%-3.3%
Margin %13.8%14.0%13.5%
EV / EBITDA16.7x15.5x14.7x
EBIT$54.6M$58.6M$56.5M
YoY %+7.2%-3.6%
Margin %10.7%11.2%10.7%
EV / EBIT21.5x19.5x18.5x
Net Income$36.7M$31.4M$29.7M
YoY %-14.4%-5.5%
Net Margin7.2%6.0%5.6%
EPS (GAAP)$0.77$0.66$0.63
YoY %-14.3%-4.5%